NewLink Genetics Corporation
Three smaller cancer treatment biotechs -- NewLink Genetics (NASDAQ: NLNK), ImmunoGen (NASDAQ: IMGN) and Insys Therapeutics (NASDAQ: INSY) -- recently rallied, thanks to fresh investor interest in their technologies. These three companies are all working on innovative ways to revolutionize cancer treatments, and could experience considerable upside growth if their pipeline treatments are approved.
Could immunotherapy replace chemotherapy?
NewLink Genetics focuses on two main platforms -- HyperAcute immunotherapy and IDO pathway inhibitors.
The more »
As a recently retired R&D specialist for both developmental biotech and Big Pharma, I have seen a lot of bright developmental companies over the last 20 years. I always found those with a new therapeutic approach as being the most attractive, many of which flew under-the-radar. In this article, I am looking at three such companies that are worthy of your due diligence.
An up-and-coming approach that targets Cancer more »
Big Pharma gets the headlines at ASCO, but smaller up-and-coming biotechnology companies also produce breakthroughs in the treatment of cancer. Let’s see which two biotechs made their presence known at this year’s ASCO.
Expanding a Growing Well-Diversified Cancer Fighting Drug
One strategy that has proven to be effective over time in determining whether a stock is moving higher is insider accumulation, due to one simple reason. Insiders sell shares for a variety of reason, but they buy them, just like us, because they believe the stock will move higher. Furthermore, they have an enviable vantage point of their company's day-to-day operations, and they may also have a large investment more »
Purchasing small biotech companies can be compared to purchasing a lottery ticket. If their blockbuster drug gets approved by the FDA, then the stock doubles in a day. If the drug does not get approved, the company putters along, reevaluating their position. That is why I strongly believe that long-term investors should not focus on small biotechnology companies, yet every once and a while, investors can buy a lottery ticket more »
By George S. Mack, The Life Sciences Report
For more interviews with sector experts and analysts, please sign up for our newsletter at www.thelifesciencesreport.com.
Immunity is cancer's enemy
The complexity of the mammalian immune system is daunting for molecular biologists and drug developers, but incremental progress has brought biotech and biopharma to the point where small molecules and biologics are being developed with more »